サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がん用生物学的毒素製剤の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
市場調査レポート
商品コード
1409002

がん用生物学的毒素製剤の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）

Global Cancer Biological Toxins Drug Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 286 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
がん用生物学的毒素製剤の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
出版日: 2024年01月01日
発行: Value Market Research
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん用生物学的毒素製剤の市場規模は、2022年の151億9,000万米ドルから、2030年には265億7,000万米ドル近くに達し、調査期間2023年～2030年のCAGRは7.24%と推定されます。

がん用生物学的毒素製剤は、特定の生物学的物質の毒性を利用してがんを治療するように設計された治療薬のクラスを指します。これらの薬剤は、多くの場合細菌、植物、その他の生物に由来する天然毒素を利用しており、がん細胞を選択的に標的にして死滅させます。これらの薬剤のコンセプトは、健康な細胞へのダメージを最小限に抑えながら、がん細胞に対するこれらの毒素の特異性を利用することです。

市場力学

免疫毒素のような標的療法を含むがん用生物学的毒素製剤市場は、がん治療の状況を形成するいくつかの要因によって牽引されています。精密医療の進歩により、がん特有の遺伝的・分子的特徴に合わせた治療法の開発が可能になりました。生物学的製剤を含む重要な要素である免疫療法は有望であり、このセグメントの成長に寄与しています。がん領域における個別化医療への動向と、規制当局の承認につながる臨床試験の成功が、市場の前進を後押ししています。がん研究への投資の増加、世界のがん罹患率の上昇、製薬企業と研究機関の共同研究は、革新的な薬剤の発見と開発を促進しています。バイオテクノロジーの進歩と患者・医療従事者の意識の高まりは、がん治療における生物学的毒素の採用にさらに影響を与えています。支援的な規制環境と政府のイニシアチブは、標的がん治療の進展と成功に必要な枠組みを提供する上で重要な役割を果たしており、がん用生物学的毒素製剤市場のダイナミックな状況に貢献しています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、がん用生物学的毒素製剤の世界市場における各セグメントを包括的に評価することもできます。がん用生物学的毒素製剤産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの地域展望をカバーし、がん用生物学的毒素製剤市場の現在と将来の需要を明らかにしています。さらに、すべての主要地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 がん用生物学的毒素製剤- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 がん用生物学的毒素製剤の世界市場分析：製品別

  • 製品別概要
  • 実績データと予測データ
  • 製品別分析
  • サイトカイン
  • 血球成長因子
  • がん成長阻害剤
  • ワクチン
  • モノクローナル抗体

第6章 がん用生物学的毒素製剤の世界市場分析：薬剤タイプ別

  • 薬剤タイプ別概要
  • 実績データと予測データ
  • 薬剤タイプ別分析
  • ホルモン療法
  • 免疫療法
  • 標的療法
  • 化学療法

第7章 がん用生物学的毒素製剤の世界市場分析：がんの性質別

  • がんの性質別概要
  • 実績データと予測データ
  • がんの性質別分析
  • 膀胱がん
  • 腎臓がん
  • 子宮頸がん
  • 食道がん
  • 肝臓がん
  • 前立腺がん
  • 乳がん
  • 大腸がん
  • 胃がん
  • 肺がん
  • その他

第8章 がん用生物学的毒素製剤の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 通信販売薬局
  • 小売薬局
  • 院内薬局

第9章 がん用生物学的毒素製剤の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要・実績・予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要・実績・予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要・実績・予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要・実績・予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要・実績・予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第10章 がん用生物学的毒素製剤企業の競合情勢

  • がん用生物学的毒素製剤の市場競争
  • 提携/協力/協定
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Exelixis Inc.
  • Bayer AG
  • Amgen Inc.
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Merck & Co.
  • Johnson & Johnson
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Xenova Biomedix
  • Neopharma
  • Roche
  • Seattle Genetics
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Product (USD MN)
  • Cytokines Market Sales by Geography (USD MN)
  • Blood Cell Growth Factors Market Sales by Geography (USD MN)
  • Cancer Growth Blockers Market Sales by Geography (USD MN)
  • Vaccines Market Sales by Geography (USD MN)
  • Monoclonal Antibodies Market Sales by Geography (USD MN)
  • Analysis Market by Drug Type (USD MN)
  • Hormonal Therapy Market Sales by Geography (USD MN)
  • Immunotherapy Market Sales by Geography (USD MN)
  • Targeted Therapy Market Sales by Geography (USD MN)
  • Chemotherapy Market Sales by Geography (USD MN)
  • Analysis by Inclination (USD MN)
  • Bladder Cancer Market Sales by Geography (USD MN)
  • Kidney Cancer Market Sales by Geography (USD MN)
  • Cervical Cancer Market Sales by Geography (USD MN)
  • Esophagus Cancer Market Sales by Geography (USD MN)
  • Liver Cancer Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Colorectal Cancer Market Sales by Geography (USD MN)
  • Stomach Cancer Market Sales by Geography (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Mail-Order Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Global Cancer Biological Toxins Drug Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cancer Biological Toxins Drug Report
  • Market Research Process
  • Market Research Methodology
  • Global Cancer Biological Toxins Drug Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product
  • Market Attractiveness Analysis by Drug Type
  • Market Attractiveness Analysis by Inclination
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product (USD MN)
  • Cytokines Market Sales by Geography (USD MN)
  • Blood Cell Growth Factors Market Sales by Geography (USD MN)
  • Cancer Growth Blockers Market Sales by Geography (USD MN)
  • Vaccines Market Sales by Geography (USD MN)
  • Monoclonal Antibodies Market Sales by Geography (USD MN)
  • Global Market Analysis by Drug Type (USD MN)
  • Hormonal Therapy Market Sales by Geography (USD MN)
  • Immunotherapy Market Sales by Geography (USD MN)
  • Targeted Therapy Market Sales by Geography (USD MN)
  • Chemotherapy Market Sales by Geography (USD MN)
  • Global Market Analysis by Inclination (USD MN)
  • Bladder Cancer Market Sales by Geography (USD MN)
  • Kidney Cancer Market Sales by Geography (USD MN)
  • Cervical Cancer Market Sales by Geography (USD MN)
  • Esophagus Cancer Market Sales by Geography (USD MN)
  • Liver Cancer Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Colorectal Cancer Market Sales by Geography (USD MN)
  • Stomach Cancer Market Sales by Geography (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Mail-Order Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112113244

The global demand for Cancer Biological Toxins Drug Market is presumed to reach the market size of nearly USD 26.57 BN by 2030 from USD 15.19 BN in 2022 with a CAGR of 7.24% under the study period 2023 - 2030.

Cancer biological toxins drugs refer to a class of therapeutic agents designed to treat cancer by leveraging the toxic properties of certain biological substances. These drugs utilize natural toxins, often derived from bacteria, plants, or other organisms, which selectively target and kill cancer cells. The concept behind these drugs is to exploit the specificity of these toxins for cancer cells while minimizing damage to healthy cells.

MARKET DYNAMICS

The Cancer biological toxins drug market, encompassing targeted therapies like immunotoxins, is driven by several factors shaping the landscape of cancer treatment. Advances in precision medicine enable the development of therapies tailored to the specific genetic and molecular characteristics of cancer. Immunotherapy, a key component involving biological agents, has shown promise, contributing to the growth of this segment. The trend towards personalized medicine in oncology and the success of clinical trials leading to regulatory approvals propel the market forward. Increasing investments in cancer research, rising cancer incidence globally, and collaborations between pharmaceutical entities and research institutions foster the discovery and development of innovative drugs. Advances in biotechnology and heightened patient and healthcare professional awareness further influence the adoption of biological toxins in cancer treatment. Supportive regulatory environments and government initiatives play a crucial role in providing the necessary framework for the progress and success of targeted cancer therapies, contributing to the dynamic landscape of the cancer biological toxins drug market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer biological toxins drug. The growth and trends of cancer biological toxins drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cancer biological toxins drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Cytokines
  • Blood Cell Growth Factors
  • Cancer Growth Blockers
  • Vaccines
  • Monoclonal Antibodies

By Drug Type

  • Hormonal Therapy
  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy

By Inclination

  • Bladder Cancer
  • Kidney Cancer
  • Cervical Cancer
  • Esophagus Cancer
  • Liver Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Lung Cancer
  • Others

By Distribution Channel

  • Mail-Order Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Biological Toxins Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Biological Toxins Drug market include Exelixis, Inc., Bayer AG, Amgen Inc., Sanofi, Pfizer Inc, Novartis AG, Merck & Co., Johnson & Johnson, Celgene Corporation, Bristol-Myers Squibb Company, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., Xenova Biomedix, Neopharma, Roche, Seattle Genetics, Sanofi, Research Corporation Technologies, Molecular Template, Eisai, Angimmune, Novartis International AG, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CANCER BIOLOGICAL TOXINS DRUG - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Drug Type
    • 3.7.3 Market Attractiveness Analysis By Inclination
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CANCER BIOLOGICAL TOXINS DRUG MARKET ANALYSIS BY PRODUCT

  • 5.1 Overview by Product
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Product
  • 5.4 Cytokines Historic and Forecast Sales by Regions
  • 5.5 Blood Cell Growth Factors Historic and Forecast Sales by Regions
  • 5.6 Cancer Growth Blockers Historic and Forecast Sales by Regions
  • 5.7 Vaccines Historic and Forecast Sales by Regions
  • 5.8 Monoclonal Antibodies Historic and Forecast Sales by Regions

6 . GLOBAL CANCER BIOLOGICAL TOXINS DRUG MARKET ANALYSIS BY DRUG TYPE

  • 6.1 Overview by Drug Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Type
  • 6.4 Hormonal Therapy Historic and Forecast Sales by Regions
  • 6.5 Immunotherapy Historic and Forecast Sales by Regions
  • 6.6 Targeted Therapy Historic and Forecast Sales by Regions
  • 6.7 Chemotherapy Historic and Forecast Sales by Regions

7 . GLOBAL CANCER BIOLOGICAL TOXINS DRUG MARKET ANALYSIS BY INCLINATION

  • 7.1 Overview by Inclination
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Inclination
  • 7.4 Bladder Cancer Historic and Forecast Sales by Regions
  • 7.5 Kidney Cancer Historic and Forecast Sales by Regions
  • 7.6 Cervical Cancer Historic and Forecast Sales by Regions
  • 7.7 Esophagus Cancer Historic and Forecast Sales by Regions
  • 7.8 Liver Cancer Historic and Forecast Sales by Regions
  • 7.9 Prostate Cancer Historic and Forecast Sales by Regions
  • 7.10. Breast Cancer Historic and Forecast Sales by Regions
  • 7.11 Colorectal Cancer Historic and Forecast Sales by Regions
  • 7.12 Stomach Cancer Historic and Forecast Sales by Regions
  • 7.13 Lung Cancer Historic and Forecast Sales by Regions
  • 7.14 Others Historic and Forecast Sales by Regions

8 . GLOBAL CANCER BIOLOGICAL TOXINS DRUG MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1 Overview by Distribution Channel
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Distribution Channel
  • 8.4 Mail-Order Pharmacies Historic and Forecast Sales by Regions
  • 8.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 8.6 Hospital Pharmacies Historic and Forecast Sales by Regions

9 . GLOBAL CANCER BIOLOGICAL TOXINS DRUG MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. South East Asia Sales Analysis
    • 9.5.10. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CANCER BIOLOGICAL TOXINS DRUG COMPANIES

  • 10.1. Cancer Biological Toxins Drug Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CANCER BIOLOGICAL TOXINS DRUG INDUSTRY

  • 11.1. Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Exelixis Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Bayer AG
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Amgen Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Sanofi
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Pfizer Inc
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Novartis AG
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Merck & Co.
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Johnson & Johnson
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Celgene Corporation
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Bristol-Myers Squibb Company
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. AstraZeneca PLC
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Astellas Pharma Inc.
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. AbbVie Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Xenova Biomedix
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Neopharma
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments
  • 11.18. Roche
    • 11.18.1. Company Overview
    • 11.18.2. Company Revenue
    • 11.18.3. Products
    • 11.18.4. Recent Developments
  • 11.19. Seattle Genetics
    • 11.19.1. Company Overview
    • 11.19.2. Company Revenue
    • 11.19.3. Products
    • 11.19.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies